Biomarkers and Pathology

One imperative part of Pathology in the assessment of bosom malignancy is biomarker testing, particularly the precise appraisal of the estrogen receptor (ER), progesterone receptor (PR), and Her2 status of a patient's bosom tumor. Biomarkers can be prognostic, prescient, or both. Prognostic biomarkers are free measures of forecast to such an extent that the nearness or nonappearance of the biomarker is connected with a patient's general clinical result (i.e., danger of repeat and mortality).

    Related Conference of Biomarkers and Pathology

    March 18-19, 2024

    5th Global Summit on Oncology and Hematology

    Zurich, Switzerland
    June 10-11, 2024

    8th Global Meeting on Oncology and Radiology

    Barcelona, Spain
    July 11-12, 2024

    24th World Congress on Cancer and Diagnostics

    Vancouver, Canada
    July 18-19, 2024

    14th World Congress on Breast Cancer

    Paris, France
    September 19-20, 2024

    25th World Congress on Cancer Summit

    Paris, France

    Biomarkers and Pathology Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in